View by type:
Articles (4214)
IOM and Gavi working together to give the most vulnerable ‘a good start’ in South Sudan
This week Gavi signed a historic agreement with the International Organization for Migration (IOM) to improve immunisation coverage for migrants and forcibly displaced persons around the world. IOM’s South Sudan Communications Officer, Liatile…
Ensuring safety of COVID-19 vaccines
CEPI spoke with vaccine safety expert, Dr Robert Chen, Science Director of The Brighton Collaboration – the largest global organisation of scientific experts on vaccine safety – about how vaccine safety is assessed in clinical trials and how…
Anxiety, depression and insomnia: the impact of COVID-19 on mental health
COVID-19 patients are at an increased risk of being diagnosed with anxiety, depression or insomnia. Here’s a closer look at how the SARS-CoV-2 virus can impact your mental health.
Why the Oxford AstraZeneca vaccine is now a global game changer
The global pandemic is far from over, but this latest in a series of welcome announcements brings renewed hope even if several hurdles remain.
Gavi and IOM join forces to improve immunisation coverage for migrants
Memorandum of understanding signed today will strengthen collaboration on vaccination efforts and related health services for migrants and forcibly displaced persons across the world
The longest mile in the COVID-19 vaccine cold chain
Promises of COVID-19 vaccine doses for developing countries will face challenges along the crucial cold chain.
Gavi statement on AstraZeneca/Oxford interim efficacy data
Geneva, 24 November 2020 – Gavi, the Vaccine Alliance, as co-lead of COVAX and administrator of the COVAX Facility, welcomes the release of interim efficacy data for the AstraZeneca/Oxford COVID-19 vaccine candidate.
COVID-19 ‘Vaccine for the World’ shows up to 90% efficacy
Interim analysis of the AstraZeneca/Oxford COVID-19 vaccine candidate – to which Gavi has secured access – suggests an efficacy of 62– 90%. Crucially, the vaccine can be administered and distributed using existing health care and supply chain…
Oxford vaccine results are in: here's how to ensure it is used
The Oxford vaccine – developed in partnership with AstraZeneca – stops 70% of people developing COVID symptoms, and, depending on how the doses are given, may even protect up to 90% of people.
Resumed immunization campaigns are critical to preventing COVID-19 as well as polio
Local adaptation and innovation has allowed the resumption of polio immunization campaigns – and points the way to more effective, community-based delivery of a whole range of basic health services.
COVID-19 antibody levels could fall faster in men than women
New research suggesting that antibodies reduce faster in men compared with women could have implications for vaccine development.
Although antimicrobial resistance has been a known and growing problem for decades, only one new class of antibiotics has been discovered since 1984. Tackling AMR requires a fundamental change in how new antibiotics are valued, and government…
